Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280690 | 0.92 | OPRL1 (1.00) | OPRL1OPRM1OPRK1HTR1AOPRD1 | |
| SCHEMBL14529401 | 0.81 | OPRL1 (0.78) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4881220 | 0.77 | OPRL1 (0.70) | OPRL1OPRM1OPRK1HTR1AOPRD1 | |
| SCHEMBL14280686 | 0.77 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1SLC6A4 | |
| SCHEMBL4881216 | 0.76 | OPRL1 (0.68) | OPRL1OPRM1OPRK1HTR1AOPRD1 | |
| SCHEMBL5147562 | 0.76 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4673580 | 0.76 | HTR1B (0.71) | OPRL1OPRM1OPRK1HTR1ASLC6A4 | |
| SCHEMBL4880602 | 0.73 | OPRM1 (0.75) | OPRL1OPRM1OPRK1HTR1ASLC6A4 | |
| SCHEMBL2244929 | 0.73 | OPRL1 (0.63) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL6642178 | 0.72 | HTR1A (1.00) | OPRL1OPRM1OPRK1HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007050381-A2 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | OPRL1 2/4885OPRM1 11/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.